SUMO3 and neoplasm: The results showed that there was a higher proportion of patients who did not receive radiotherapy among the PAAD patients with high expression of SUMO2 (Figure 2A) (Supplementary Material S1), while there was a higher proportion of patients with a history of smoking, higher tumor grade, and higher tumor stage among the PAAD patients with high expression of SUMO3 (Figure 2A) (Supplementary Material S1).